Published in Stem Cell Res Ther on September 29, 2017
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol (2007) 6.63
Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J (2003) 5.61
Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells (2002) 4.62
Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone (2003) 4.61
Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc (2009) 4.47
Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A (1996) 4.33
Rapamycin decelerates cellular senescence. Cell Cycle (2009) 3.97
Stem cells, ageing and the quest for immortality. Nature (2006) 3.89
Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells (2004) 3.15
The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity (1997) 3.11
Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell (2008) 3.08
Rejuvenation of the muscle stem cell population restores strength to injured aged muscles. Nat Med (2014) 2.99
TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol (2007) 2.49
Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal (2010) 2.44
A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol (1997) 2.31
Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol (2005) 2.24
In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. Stem Cells (2010) 2.18
The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet (2012) 2.13
Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res (2008) 2.02
Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene (2006) 2.01
Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering. J Orthop Res (2007) 1.89
Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy (2014) 1.69
Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci (2013) 1.64
TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene (2003) 1.57
Review: ex vivo engineering of living tissues with adult stem cells. Tissue Eng (2006) 1.56
p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One (2008) 1.55
TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett (1998) 1.54
Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy (2008) 1.51
The origins of mesenchymal stromal cell heterogeneity. Stem Cell Rev (2011) 1.43
Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem (2012) 1.41
How to track cellular aging of mesenchymal stromal cells? Aging (Albany NY) (2010) 1.34
Clonal analysis of the proliferation potential of human bone marrow mesenchymal stem cells as a function of potency. Biotechnol Bioeng (2011) 1.24
Human mesenchymal stem cell-replicative senescence and oxidative stress are closely linked to aneuploidy. Cell Death Dis (2013) 1.16
Comparison of various kinds of bone marrow stem cells for the repair of infarcted myocardium: single clonally purified non-hematopoietic mesenchymal stem cells serve as a superior source. J Cell Biochem (2006) 1.13
Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res (2005) 1.12
p53 regulates the proliferation, differentiation and spontaneous transformation of mesenchymal stem cells. Exp Cell Res (2009) 1.09
Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential. Cytotherapy (2004) 1.09
Small-molecule antagonist of macrophage migration inhibitory factor enhances migratory response of mesenchymal stem cells to bronchial epithelial cells. Tissue Eng Part A (2009) 1.08
Invade or proliferate? Two contrasting events in malignant behavior governed by p16(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res (2003) 1.02
The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther (2000) 1.01
Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene (1997) 1.00
Flow cytometric discrimination of mesenchymal progenitor cells from bone marrow-adherent cell populations using CD34/44/45(-) and Sca-1(+) markers. J Orthop Sci (2007) 0.97
Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors. Biochem Biophys Res Commun (2005) 0.94
Migratory response of mesenchymal stem cells to macrophage migration inhibitory factor and its antagonist as a function of colony-forming efficiency. Biotechnol Lett (2009) 0.93
TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT. PLoS One (2011) 0.92
Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells (2008) 0.91
Cell-surface expression of neuron-glial antigen 2 (NG2) and melanoma cell adhesion molecule (CD146) in heterogeneous cultures of marrow-derived mesenchymal stem cells. Tissue Eng Part A (2013) 0.91
The effect of donor variation and senescence on endothelial differentiation of human mesenchymal stromal cells. Tissue Eng Part A (2013) 0.91
Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells. Cancer Sci (2013) 0.90
Spatial composition of prostate cancer spheroids in mixed and static cultures. Tissue Eng (2004) 0.90
Stem cells are resistant to TRAIL receptor-mediated apoptosis. J Cell Mol Med (2010) 0.89
Licensing by Inflammatory Cytokines Abolishes Heterogeneity of Immunosuppressive Function of Mesenchymal Stem Cell Population. Stem Cells Dev (2015) 0.84
Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function. Stem Cells (2015) 0.83
Effects of estrogen on stress-induced premature senescence of vascular smooth muscle cells: a novel mechanism for the "time window theory" of menopausal hormone therapy. Atherosclerosis (2011) 0.82
Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma. Stem Cells Dev (2013) 0.79
Evaluation of premature senescence and senescence biomarkers in carcinoma cells and xenograft mice exposed to single or fractionated irradiation. Oncol Rep (2014) 0.77